UDCA treatment against COVID-19: Do we have enough clinical evidence for drug repurposing?
Description
Ursodeoxycholic acid (UDCA), an off-patent drug used to treat liver disease, is able to block SARS-CoV-2 entry into the cells downregulating ACE2 expression, a promising strategy to protect against infection. In this light, John et al. have recently
